DIJON, France–(BUSINESS WIRE)–Regulatory News:
ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), a biopharmaceutical group specialized in precision medicine, announces its FY 2020 financial results and its outlook for 2021 and beyond.
Philippe GENNE, Oncodesign’s Chairman and Chief Executive, says: “Oncodesign has not only proven its resilience and the strength of its economic model, the Company has also shown its agility, its ingenuity and its determination within the context of an unprecedented global public health crisis. Oncodesign has been able to cope with the challenges of a turbulent 2020, generating revenue of €25.5 million, similar to the figure recorded in 2019 – a record year that had seen growth of +34% – with €38.5 million in operating revenue and an operating profit twice that observed in 2019 at €1.5 million and a net profit of €2.1 million. We have achieved these results whilst maintaining our substantial R&D investments at €10.8 million, or 40% of revenue.
The Service BU recorded total revenue of €29.6 million, including €21.1 million generated with clients and €8.5 million recorded on behalf of the Biotech BU, with an EBITDA of 11.4% versus 3% in 2019. A record order book for the Service BU of €26 million (+36%, including €3 million associated with the new COVID-19 offer) is also worth noting. The substantial improvement in its EBITDA is proof of the total commitment of our teams to the strategy defined for…
